Perrigo
- Country
- 🇮🇪Ireland
- Ownership
- Private
- Employees
- 9.1K
- Market Cap
- $3.9B
- Introduction
Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Comparative Study for the Evaluation of Two Medical Devices on the Treatment of Head Lice Infestation
- Conditions
- Head Lice Infestation
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Perrigo CSCI
- Target Recruit Count
- 136
- Registration Number
- NCT06057506
- Locations
- 🇲🇺
Insight Research, Quatre Bornes, Mauritius
Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation
- Conditions
- Head Lice
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Perrigo CSCI
- Target Recruit Count
- 136
- Registration Number
- NCT05379114
- Locations
- 🇲🇺
Céline Lhéritier, Quatre Bornes, Mauritius
Effects of Arterin Cholesterol for Reduction of Lipid Levels
- Conditions
- Blood Cholesterol LowersLDL-C
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Perrigo CSCI
- Target Recruit Count
- 114
- Registration Number
- NCT04749784
- Locations
- 🇩🇪
analyze & realize GmbH, Berlin, Germany
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
- Conditions
- OverweightObesity
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Perrigo CSCI
- Target Recruit Count
- 178
- Registration Number
- NCT04086797
- Locations
- 🇩🇪
analyze & realize GmbH, Berlin, Germany